![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Sanofi, Regeneron Allowed to Sell Cholesterol Drug, Pending an Appeal
Sanofi, Regeneron Allowed to Sell Cholesterol Drug, Pending an Appeal
February 15, 2017
A federal appeals court temporarily suspended a permanent injunction that bars Sanofi and Regeneron from selling their cholesterol drug Praluent, pending a final ruling on an appeal.
The U.S. Court of Appeals for the Federal Circuit granted the stay based on four factors, the most critical being whether the companies showed a strong likelihood to prevail in their appeal and whether they would be irreparably damaged in the absence of a stay.
Potential damages to other interested parties and public interests factored into the decision, but to a lesser degree, the court said. A final decision on the appeal is expected in the next several months.
Upcoming Events
-
21Oct